Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Potent, orally active AVP receptor antagonist increases urine output in rats

July 14, 1999

KRP-197: new bladder-selective antimuscarinic agent in clinical trials for bladder dysfunction

July 14, 1999

Two more European countries permit phase II studies of resiniferatoxin

July 8, 1999

Uroselective alpha-adrenoceptor blocker GYKI-16084 assessed in BPH and spinal cord injury models

July 7, 1999

Angiotensin II blockade as a strategy for preventing renal allograft nephropathy

July 2, 1999

Nippon Kayaku's new agents for micturition disorders

July 1, 1999

Shire reports positive phase II results for Lambda

June 30, 1999

FDA approves 15-mg Ditropan XL tablets

June 30, 1999

Zeria designs dual-action arylpiperazines for BPH

June 28, 1999

WAY-133537: safe and effective agent for bladder instability

June 28, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...